ARID1A mutation	Non Small Cell Lung Cancer	ARID1A mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
ARID1A mutation	Non Small Cell Lung Cancer	ARID1A mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ARID1A mutation	Renal Cell Carcinoma	ARID1A mutation	Renal Cell Carcinoma	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	NXP900 Sensitive: B - Late Trials NXP900 Sensitive : B	NXP900 Sensitive: B - Late Trials NXP900 Sensitive : B
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	NXP800 Sensitive: B - Late Trials NXP800 Sensitive : B	NXP800 Sensitive: B - Late Trials NXP800 Sensitive : B
ARID1A mutation	Endometrial Cancer	ARID1A mutation	Endometrial Cancer	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2
ARID1A mutation	Hepatocellular Cancer	ARID1A mutation	Hepatocellular Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Cholangiocarcinoma	ARID1A mutation	Cholangiocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Gastric Cancer	ARID1A mutation	Gastric Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Esophageal Adenocarcinoma	ARID1A mutation	Esophageal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Colorectal Cancer	ARID1A mutation	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
ARID1A mutation	Gastrointestinal Cancer	ARID1A mutation	Gastrointestinal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Head and Neck Cancer	ARID1A mutation	Head and Neck Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Breast Cancer	ARID1A mutation	Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Bladder Cancer	ARID1A mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Endometrial Adenocarcinoma	ARID1A mutation	Endometrial Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Pancreatic Ductal Adenocarcinoma	ARID1A mutation	Pancreatic Ductal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Melanoma	ARID1A mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Neuroendocrine Tumor	ARID1A mutation	Neuroendocrine Tumor	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
ARID1A mutation	Solid Tumor	ARID1A mutation	Solid Tumor	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
ARID1A mutation	Cervical Cancer	ARID1A mutation	Cervical Cancer	bevacizumab + rucaparib Sensitive: C3 – Early Trials bevacizumab + rucaparib Sensitive : C3	bevacizumab + rucaparib Sensitive: C3 – Early Trials bevacizumab + rucaparib Sensitive : C3
ARID1A mutation	Endometrial Cancer	ARID1A mutation	Endometrial Cancer	bevacizumab + rucaparib Sensitive: C3 – Early Trials bevacizumab + rucaparib Sensitive : C3	bevacizumab + rucaparib Sensitive: C3 – Early Trials bevacizumab + rucaparib Sensitive : C3
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	pembrolizumab + anlotinib Sensitive: C3 – Early Trials pembrolizumab + anlotinib Sensitive : C3	pembrolizumab + anlotinib Sensitive: C3 – Early Trials pembrolizumab + anlotinib Sensitive : C3
ARID1A mutation	Hepatocellular Cancer	ARID1A mutation	Hepatocellular Cancer	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3
ARID1A mutation	Non Small Cell Lung Cancer	ARID1A mutation	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
ARID1A mutation	Urothelial Cancer	ARID1A mutation	Urothelial Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1A mutation	Cholangiocarcinoma	ARID1A mutation	Cholangiocarcinoma	cisplatin + gemcitabine Resistant: C3 – Early Trials cisplatin + gemcitabine Resistant : C3	cisplatin + gemcitabine Resistant: C3 – Early Trials cisplatin + gemcitabine Resistant : C3
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3
ARID1A mutation	Non-Hodgkin’s Lymphoma	ARID1A mutation	Non-Hodgkin’s Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3
ARID1A mutation	Cholangiocarcinoma	ARID1A mutation	Cholangiocarcinoma	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4
ARID1A mutation	Lymphoma	ARID1A mutation	Lymphoma	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4

ARID1A mutation

Associations